Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer.
biomarker
drug delivery
non-coding RNA
ovarian cancer
small extracellular vesicles
therapy
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
02
2022
accepted:
26
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Ovarian cancer (OC) is the most fatal gynecological malignancy because of its early asymptomatic nature and acquired resistance to chemotherapy. Small extracellular vesicles (sEVs) are a heterogeneous group of biological vesicles with a diameter <200 nm released by cells under physiological or pathological conditions. sEVs-derived non-coding RNAs (ncRNAs) are the essential effectors in the biological environment. sEVs-ncRNAs have critical roles in tumor progression via regulating mRNA expression of target cells to affect cell signaling. In addition, the status of parental cells can be disclosed via analyzing the composition of sEVs-ncRNAs, and their "cargoes" with specific changes can be used as key biomarkers for the diagnosis and prognosis of OC. Accumulating evidence has demonstrated that sEVs-ncRNAs are involved in multiple key processes that mediate the development of metastasis and chemotherapeutic resistance in OC: epithelial-mesenchymal transition; tumorigenicity of mesenchymal stem cells; immune evasion; angiogenesis. The nanomedicine delivery system based on engineering sEVs is expected to be a novel therapeutic strategy for OC. Insights into the biological roles of sEVs-ncRNAs in the invasion, metastasis, immune regulation, and chemoresistance of OC will contribute to discovery of novel biomarkers and molecular targets for early detection and innovative therapy. In this review, we highlight recent advances and applications of sEVs-ncRNAs in OC diagnosis and treatment. We also outline current challenges and knowledge gaps.
Identifiants
pubmed: 35662846
doi: 10.3389/fbioe.2022.876151
pii: 876151
pmc: PMC9161355
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
876151Informations de copyright
Copyright © 2022 Liu, Zhou and Tang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochim Biophys Acta. 2015 Nov;1852(11):2362-71
pubmed: 26300484
PLoS One. 2010 Jul 22;5(7):e11469
pubmed: 20661468
Trends Cell Biol. 2017 Mar;27(3):172-188
pubmed: 27979573
Nat Rev Drug Discov. 2013 May;12(5):347-57
pubmed: 23584393
J Clin Oncol. 2021 May 20;39(15):1631-1640
pubmed: 33560870
Cancers (Basel). 2021 Jul 06;13(14):
pubmed: 34298602
Dev Cell. 2020 Dec 21;55(6):784-801.e9
pubmed: 33296682
Nat Rev Cancer. 2003 Jul;3(7):502-16
pubmed: 12835670
Sci Adv. 2021 Feb 24;7(9):
pubmed: 33627414
Nat Rev Cancer. 2020 Dec;20(12):697-709
pubmed: 32958932
J Natl Cancer Inst. 2015 May 13;107(7):
pubmed: 25972604
Nat Cell Biol. 2010 Jan;12(1):19-30; sup pp 1-13
pubmed: 19966785
J Exp Clin Cancer Res. 2021 Apr 6;40(1):120
pubmed: 33823894
Cell. 2019 Apr 4;177(2):231-242
pubmed: 30951667
Gynecol Oncol. 2015 Apr;137(1):143-51
pubmed: 25579119
Lancet Oncol. 2009 Apr;10(4):327-40
pubmed: 19282241
Cell. 2001 Jul 27;106(2):145-55
pubmed: 11511343
Cancer Lett. 2017 May 1;393:60-67
pubmed: 28216373
J Exp Clin Cancer Res. 2021 Jan 23;40(1):38
pubmed: 33485367
Exp Mol Med. 2019 Mar 15;51(3):1-12
pubmed: 30872574
Lancet. 2002 Jul 27;360(9329):295-305
pubmed: 12147373
Cancer Commun (Lond). 2020 Aug;40(8):380-385
pubmed: 32428376
J Am Coll Cardiol. 2019 Mar 26;73(11):1300-1313
pubmed: 30898206
Nanomedicine (Lond). 2016 Sep;11(18):2431-41
pubmed: 27558906
J Exp Clin Cancer Res. 2019 Feb 15;38(1):81
pubmed: 30770776
Nat Cell Biol. 2009 Sep;11(9):1143-9
pubmed: 19684575
Cancer Med. 2015 May;4(5):745-58
pubmed: 25684390
Mol Ther Nucleic Acids. 2019 Sep 6;17:92-101
pubmed: 31234009
Cell Death Dis. 2021 Feb 24;12(2):210
pubmed: 33627627
Int J Mol Med. 2020 Aug;46(2):609-620
pubmed: 32626953
Cell Death Dis. 2021 Jan 7;12(1):7
pubmed: 33414439
Mol Ther Nucleic Acids. 2019 Dec 6;18:882-892
pubmed: 31751911
Cancer Immunol Res. 2018 Dec;6(12):1578-1592
pubmed: 30396909
J Natl Cancer Inst. 2015 Jul 06;107(9):
pubmed: 26150590
J Cell Commun Signal. 2020 Jun;14(2):233-244
pubmed: 32034654
Biochem Biophys Res Commun. 2020 Jun 18;527(1):153-161
pubmed: 32446360
Mol Cancer. 2019 Aug 13;18(1):124
pubmed: 31409361
J Hepatol. 2021 Dec;75(6):1301-1311
pubmed: 34271004
EMBO Rep. 2016 Aug;17(8):1184-203
pubmed: 27402548
J Extracell Vesicles. 2019 Nov 29;9(1):1697028
pubmed: 31839906
Nature. 2007 Dec 20;450(7173):1235-9
pubmed: 18097410
J Control Release. 2022 Jan;341:272-284
pubmed: 34813877
EMBO J. 2007 Oct 3;26(19):4215-27
pubmed: 17853893
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
Nanomedicine. 2020 Aug;28:102207
pubmed: 32334098
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Gynecol Oncol. 2014 Mar;132(3):739-44
pubmed: 24472409
EBioMedicine. 2018 Dec;38:100-112
pubmed: 30487062
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
ACS Nano. 2018 Nov 27;12(11):10817-10832
pubmed: 30346694
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Cancer Treat Rev. 2019 Feb;73:1-9
pubmed: 30543930
Pharmacol Rev. 2007 Jun;59(2):185-205
pubmed: 17540906
Clin Transl Med. 2021 May;11(5):e425
pubmed: 34047469
Cancer Med. 2020 Aug;9(16):5976-5988
pubmed: 32590883
Front Cell Dev Biol. 2021 Jul 08;9:673237
pubmed: 34307356
J Exp Clin Cancer Res. 2021 Mar 16;40(1):101
pubmed: 33726799
J Extracell Vesicles. 2021 Mar;10(5):e12073
pubmed: 33728031
Nat Rev Mol Cell Biol. 2020 Oct;21(10):585-606
pubmed: 32457507
Physiol Rev. 2006 Oct;86(4):1179-236
pubmed: 17015488
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560564
Sci Transl Med. 2019 Jun 5;11(495):
pubmed: 31167927
J Ovarian Res. 2018 Sep 15;11(1):81
pubmed: 30219071
Theranostics. 2021 Mar 11;11(11):5248-5266
pubmed: 33859745
Ann Oncol. 2017 Nov 1;28(suppl_8):viii13-viii15
pubmed: 29232469
J Biol Chem. 1987 Jul 5;262(19):9412-20
pubmed: 3597417
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Cell Death Dis. 2021 May 10;12(5):467
pubmed: 33972506
J Extracell Vesicles. 2020 Feb 11;9(1):1722433
pubmed: 32128073
Cell Death Dis. 2020 Dec 11;11(12):1048
pubmed: 33311449
Aging (Albany NY). 2020 Oct 7;12(19):19095-19106
pubmed: 33028742
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
J Extracell Vesicles. 2014 Dec 22;3:26913
pubmed: 25536934
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Nature. 2022 Jan;601(7893):446-451
pubmed: 34937935
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Nat Rev Genet. 2011 Nov 18;12(12):861-74
pubmed: 22094949
J Exp Clin Cancer Res. 2019 Oct 30;38(1):437
pubmed: 31666098
Nat Commun. 2018 Jun 11;9(1):2270
pubmed: 29891938
J Extracell Vesicles. 2020 Dec;10(2):e12043
pubmed: 33391635
Cancer Cytopathol. 2014 Sep;122(9):685-93
pubmed: 24888238
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Front Cell Dev Biol. 2020 Sep 17;8:553576
pubmed: 33042993
J Extracell Vesicles. 2016 Mar 24;5:29289
pubmed: 27018366
Cancers (Basel). 2019 Jun 09;11(6):
pubmed: 31181850
J Control Release. 2017 Nov 28;266:8-16
pubmed: 28916446
Cell Biol Int. 2021 Oct;45(10):2140-2149
pubmed: 34288231
Cancer Immunol Immunother. 2010 Jun;59(6):841-50
pubmed: 20043223
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
J Exp Clin Cancer Res. 2017 Apr 13;36(1):53
pubmed: 28407783
Nat Rev Cancer. 2018 Jan;18(1):5-18
pubmed: 29170536
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Cell Biochem Funct. 2021 Mar;39(2):308-316
pubmed: 32876972
Exp Mol Med. 2021 Jul;53(7):1180-1191
pubmed: 34321587
JAMA. 2011 Oct 12;306(14):1557-65
pubmed: 21990299
ACS Nano. 2021 Feb 23;15(2):3251-3263
pubmed: 33481565
Bioscience. 2015 Aug 1;65(8):783-797
pubmed: 26955082
JAMA Surg. 2020 Jul 1;155(7):572-579
pubmed: 32520332
Gynecol Oncol. 2008 Jul;110(1):13-21
pubmed: 18589210
Immunity. 2010 May 28;32(5):593-604
pubmed: 20510870
Cell. 2019 Nov 14;179(5):1033-1055
pubmed: 31730848
Analyst. 2016 Aug 07;141(15):4640-6
pubmed: 27229443
J Extracell Vesicles. 2012 Jul 11;1:
pubmed: 24009882
Trends Mol Med. 2015 Oct;21(10):595-608
pubmed: 26432017
Cancer Res. 2021 Apr 1;81(7):1639-1653
pubmed: 33547159
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
Cancers (Basel). 2021 Jun 20;13(12):
pubmed: 34203051
Front Genet. 2021 Apr 29;12:616220
pubmed: 33995475
Oncotarget. 2016 Mar 29;7(13):16923-35
pubmed: 26943577
Nat Nanotechnol. 2021 Jul;16(7):748-759
pubmed: 34211166
Cancer Res. 2016 Dec 15;76(24):7194-7207
pubmed: 27742688
Nat Commun. 2018 Oct 17;9(1):4319
pubmed: 30333487
Theranostics. 2019 Apr 13;9(9):2618-2636
pubmed: 31131057
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
J Control Release. 2021 Feb 10;330:293-304
pubmed: 33359580
Genes Cells. 2018 Nov;23(11):963-973
pubmed: 30220098
Annu Rev Biochem. 2019 Jun 20;88:487-514
pubmed: 31220978
Theranostics. 2019 Oct 18;9(26):8206-8220
pubmed: 31754391
Cancer Lett. 2018 Oct 28;435:80-91
pubmed: 30098399
J Cell Physiol. 2012 Feb;227(2):658-67
pubmed: 21465472
Mol Med Rep. 2019 May;19(5):3376-3392
pubmed: 30864705
Oncogene. 2018 Jul;37(28):3806-3821
pubmed: 29636548
J Cancer. 2019 May 12;10(9):1958-1967
pubmed: 31205555
Oncol Lett. 2019 Jun;17(6):5601-5607
pubmed: 31186782
J Ovarian Res. 2018 Mar 2;11(1):20
pubmed: 29499737
Trends Biochem Sci. 2017 Jan;42(1):42-56
pubmed: 27669649
Obstet Gynecol. 2013 Jan;121(1):25-31
pubmed: 23262924
J Nanobiotechnology. 2020 Jan 9;18(1):10
pubmed: 31918721
Cancer Res. 2004 Oct 1;64(19):7045-9
pubmed: 15466198
J Ovarian Res. 2020 Apr 26;13(1):47
pubmed: 32336272
J Extracell Vesicles. 2013 Feb 15;2:
pubmed: 24009890
Am J Cancer Res. 2021 May 15;11(5):2124-2141
pubmed: 34094673
Chem Rev. 2018 Feb 28;118(4):1917-1950
pubmed: 29384376
Cancer Biomark. 2020;27(4):485-491
pubmed: 32065786
J Extracell Vesicles. 2021 Mar;10(5):e12076
pubmed: 33747370
J Cell Physiol. 2018 Jun;233(6):4546-4562
pubmed: 29152737
Nat Commun. 2015 Sep 08;6:8094
pubmed: 26348915
Open Biol. 2020 Apr;10(4):190173
pubmed: 32343928
J Extracell Vesicles. 2019 Jul 22;8(1):1643670
pubmed: 31448068
Sci Rep. 2018 May 25;8(1):8161
pubmed: 29802284
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Cell. 2015 Nov 5;163(4):866-79
pubmed: 26522593
Cell Rep. 2019 Sep 17;28(12):3105-3119.e7
pubmed: 31533034
Adv Drug Deliv Rev. 2021 Nov;178:113969
pubmed: 34509574
CA Cancer J Clin. 2011 May-Jun;61(3):183-203
pubmed: 21521830
BMJ. 2020 Nov 9;371:m3773
pubmed: 33168565
Front Cell Dev Biol. 2021 Jun 30;9:652322
pubmed: 34277601
Cancer. 2005 Dec 15;104(12):2807-16
pubmed: 16284991
Nanoscale. 2018 Aug 7;10(29):14280-14289
pubmed: 30014056
Nat Commun. 2011;2:282
pubmed: 21505438
Nat Rev Mol Cell Biol. 2019 Sep;20(9):509-510
pubmed: 31324871
Oncol Rep. 2017 Jul;38(1):522-528
pubmed: 28586039